Follow us on Twitter
twitter icon@FreshPatents


Cirrhosis patents

      

This page is updated frequently with new Cirrhosis-related patent applications.




 Formulations of l-ornithine phenylacetate patent thumbnailFormulations of l-ornithine phenylacetate
Some embodiments of the present application are directed to oral formulations of l-ornithine phenylacetate and methods of preparing the same. These oral formulations offer alternative administration route than the standard intravenous administration of l-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders..
Ocera Therapeutics, Inc.


 Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection patent thumbnailCompositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh


 Pharmaceutical composition for preventing or treating liver diseases, containing plasmalogen precursor, plasmalogen or plasmalogen analog as effective component patent thumbnailPharmaceutical composition for preventing or treating liver diseases, containing plasmalogen precursor, plasmalogen or plasmalogen analog as effective component
The present invention relates to a pharmaceutical composition for preventing or treating liver diseases, containing a plasmalogen precursor, plasmalogen, or a plasmalogen analog as an effective component. More specifically, a plasmalogen precursor, or plasmalogen or a plasmalogen analog produced by metabolizing the plasmalogen precursor, can prevent or treat liver diseases such as hepatic steatosis, hepatitis, or liver cirrhosis, etc.
University Of Ulsan Foundation For Industry Cooper Ation


 Compositions and methods comprising a defined microbiome and methods of use thereof patent thumbnailCompositions and methods comprising a defined microbiome and methods of use thereof
The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease..
The Trustees Of The University Of Pennsylvania


 Composition and methods for treating intestinal hyperpermeability patent thumbnailComposition and methods for treating intestinal hyperpermeability
The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

 Method for producing amniotic mesenchymal stromal cell composition,  cryopreserving the same, and therapeutic agent patent thumbnailMethod for producing amniotic mesenchymal stromal cell composition, cryopreserving the same, and therapeutic agent
An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived mscs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysis and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis..
Kaneka Corporation


 Treatment of the complications of chronic liver disease patent thumbnailTreatment of the complications of chronic liver disease
Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions for reducing the progression of the clinical complications associated with portal hypertension by administering the caspase inhibitors described herein..
Conatus Pharmaceuticals, Inc.


 Advanced  treatment and management of chronic hepatitis c infection patent thumbnailAdvanced treatment and management of chronic hepatitis c infection
Chronic hepatitis c (chc) infection is associated with the development of liver fibrosis, cirrhosis and hepatocellular carcinoma. Coherently, the current study is designed to determine the therapeutic value of vitamin d as a supplement to the currently recommended treatment in saudi arabia patients diagnosed with chc and the possible correlation between vitamin d status and the target molecules in the prediction of viral response to current therapy for chc.
Umm Al-qura University


 Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers patent thumbnailClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The Unversity Of Oxford


 Novel means and methods for treating hbv infection and associated conditions patent thumbnailNovel means and methods for treating hbv infection and associated conditions
The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (cdrs) configured to bind a first antigen; and (b) (ba) a second set of six cdrs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from hepatitis b virus (hbv) small surface antigen; hbv medium surface antigen; and hbv large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (nk) cells and cytotoxic t lymphocytes (ctls). Also provided are compositions for use in a method of treating or preventing hbv infection and/or a condition caused by said hbv infection, said condition caused by said hbv infection being selected from liver cirrhosis and hepatocellular carcinoma..
Deutsches Krebsforschungszentrum


Compositions and methods for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

A novel composition for nonalcoholic fatty liver disease (nafld)

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited

Composition for preventing and treating liver fibrosis or liver cirrhosis, containing, as active ingredient, mesenchymal stem cells derived from human embryonic stem cells

The present invention relates to a composition for preventing and/or treating liver fibrosis or liver cirrhosis, which contains, as an active ingredient, mesenchymal stem cells derived from human embryonic stem cells. In the present invention, it was confirmed that mesenchymal stem cells derived from human embryonic stem cells have a preventive effect against liver fibrosis.
Seoul National University Hospital

V1a receptor agonists

Compounds of formula (i), salts thereof, and compositions and uses thereof are described. The compounds are useful as v1a vasopressin agonists, for the treatment of, e.g., complications of cirrhosis, including bacterial peritonitis, hrs2 and refractory ascites..
Ferring B.v.

P2x7 receptor agonist for use in preventing or treating kidney injury

The present invention relates to the treatment or prevention of kidney injury and in particular acute kidney injury, such as acute kidney injury associated with cirrhosis. The invention relates to the treatment or prevention of such injury by administration of an agonist of the p2x7 receptor..
Ucl Business Plc

Compositions and methods for the treatment of inflammatory bowel disease

The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Cellix Bio Private Limited

Compositions and methods for the treatment of inflammatory bowel disease

The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Epigenetic mechanisms of anti-fibrotic action for the liver

This invention demonstrates the therapeutic efficacy of yang-gan-wan (ygw) and its active components, especially in the formulation provided by sheng-pu pharmaceutials, inc., for treating and preventing liver fibrosis. This invention further demonstrates mecp2 is an important therapeutic target for ygw and its active ingredients' action against liver fibrosis and cirrhosis..

Biomarker composite test for hepatic vein pressure gradient and cirrhosis treatment

Diagnostic biomarker panel, method, kit, and device for diagnosing the severity and/or prognosis of cirrhosis are provided. More specifically, the invention provides a novel biomarker panel correlating to hvpg and esophageal varices.
The Regents Of The University Of California

Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers

The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The University Of Oxford

Gene signatures of inflammatory disorders that relate to the liver

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (crohn's and ulcerative colitis).
Institut National De La Recherche Agronomique

Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-pdgf receptors; (ii) synaptophysin; (iii) zvegf3; (iv) ccr1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases mmp 2 and mmp9; (viii) matrix metalloproteinase inhibitors timp1 and tmp2; (ix) integrins; (x) tfg-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.. .
Galectin Therapeutics, Inc.

Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing dicarboxylic acid bisamide derivatives

Or pharmaceutically acceptable salts thereof, which are able to form complexes with or chelate metal ions. The invention also relates to the use of said compounds as an agent for the prevention and/or treatment of cardiovascular, viral, cancer, neurodegenerative and inflammatory diseases, diabetes, age-related diseases, diseases caused by microbial toxins, alcoholism and alcoholic cirrhosis, anaemia, porphyria cutanea tarda, and transition metal salt poisoning.

Benzidine derivative, preparing same, and pharmaceutical composition containing benzidine derivative for treating liver disease caused by hepatitis c virus

The disclosed compounds have antiviral activity against c-type virus, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating liver disease caused by hepatitis c virus. The benzidine derivative according to the present invention has excellent antiviral activity against hepatitis c virus and exhibits excellent medicinal activity in the living body, and thus the pharmaceutical composition containing the same as an active ingredient can be useful as a pharmaceutical composition for preventing or treating liver disease, such as acute hepatitis c, chronic hepatitis c, cirrhosis, or hepatocellular carcinoma, caused by c-type virus..
Seoul National University R&db Foundation

Trail receptor agonists for treatment of fibrotic disease

Pro-apoptotic agents such as ligands and agonists of agonistic trail receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (hscs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (pscs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells.
Theraly Pharmaceuticals, Inc.

Devices and methods for intrahepatic shunts

The invention provides methods and devices for treating liver cirrhosis or portal hypertension by creating an intrahepatic shunt, or new passage, from a portal vein of a patient to a hepatic vein using a device with intravascular imaging capabilities and pressure sensing capabilities or positioning mechanisms. The integration of intravascular imaging aids in the precise placement of the shunt and pressure measurement may verify successful shunt creation.
Volcano Corporation

Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis

The present invention relates to compounds of the formula i and in particular medicaments comprising at least one compound of the formula i for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which adamts5 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.. .
Merck Patent Gmbh

Ligands that bind tgf-beta receptor ii

The disclosure provides an anti-tgfbetarii immunoglobulin single variable domain. Suitably, an anti-tgfbetarii immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of seq id no:1-28 having up to 5 amino acid substitutions, deletions or additions.
Glaxo Group Limited

Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders

The present invention relates to certain substituted tricyclic acid derivatives of formula (i) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the s1p1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer..
Arena Pharmaceuticals, Inc.

Methods modulating immunoregulatory effect of stem cells

The present invention provides methods or kits with inflammatory cytokines to pretreat 1-iscs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, parkinson's disease, chronic infections, and gvhd. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (jvfscs)..
Rutgers, The State University Of New Jersey

Saquinavir-no for immunomodulation

The nitric ester of saquinavir, or its non-toxic salts, solvates or crystalline/polymorphic forms, i useful in the treatment of autoimmune diseases, particularly in disease mediated by pro-inflammatory cytokines. Examples of diseases which may be treated include idiopathic addison's disease, autoimmune hepatitis, biliary cirrhosis, primary sclerosing cholangitis, guillain barré syndrome, hashimoto's thyroiditis, psoriasis, rheumatoid arthritis, sjogren's syndrome, systemic lupus erythematous, type 1 diabetes mellitus and uveitis of ischemia-reperfusion, graft versus host diseases, graft rejection, endo and exo-toxemia and gouty arthritis..

Methods of diagnosing liver cancer in a subject and a kit for diagnosing liver cancer

Disclosed are methods of diagnosing liver cancer in a subject as well as methods of assessing the risk of a subject having chronic hepatitis and liver cirrhosis of developing liver cancer. Also disclosed are kits for the diagnosis of liver cancer..
Singapore Health Services Pte Ltd

Ddr2 inhibitors for the treatment of osteoarthritis

The present invention relates to compounds of the formula i and in particular medicaments comprising at least one compound of the formula i for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which ddr2 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.. .
Merck Patent Gmbh

Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and/or salt thereof for improving liver functioning

A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including mmps and timps, and so it can inhibit liver fibrosis.
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Methods and compositions for diagnosis of inflammatory liver disease

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (e3) levels, either alone or with levels of eotaxin-1 (e1), and optionally, with levels of ccl22 and, further optionally, with levels of il15.
Medizinische Hochschule Hannover



Cirrhosis topics:
  • Hypertension
  • Vascular Disease
  • Endothelial Dysfunction
  • Endothelial
  • Dysfunction
  • Cardiovascular Disease
  • Cardiovascular
  • Hepatocellular Carcinoma
  • Pharmaceutically Acceptable Salt
  • Pharmaceutically Acceptable Salts
  • Nephropathy
  • Nucleic Acid
  • Inflammation
  • Recombinant
  • Wound Healing


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Cirrhosis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cirrhosis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.6972

    file did exist - 2443

    2 - 1 - 52